IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.342
+0.009 (2.55%)
Nov 21, 2024, 11:55 AM EST - Market open
IGC Pharma Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 1.18 | 1.35 | 0.91 | 0.4 | 0.9 | 4.07 | Upgrade
|
| Revenue Growth (YoY) | -11.91% | 47.64% | 129.47% | -55.79% | -77.95% | -20.41% | Upgrade
|
| Cost of Revenue | 0.52 | 0.61 | 0.47 | 0.2 | 0.79 | 3.96 | Upgrade
|
| Gross Profit | 0.67 | 0.73 | 0.44 | 0.19 | 0.11 | 0.12 | Upgrade
|
| Selling, General & Admin | 6.43 | 6.76 | 8.55 | 12.46 | 7.91 | 5.97 | Upgrade
|
| Research & Development | 3.56 | 3.77 | 3.46 | 2.33 | 0.93 | 1.01 | Upgrade
|
| Operating Expenses | 9.99 | 10.53 | 12.01 | 14.79 | 8.84 | 6.98 | Upgrade
|
| Operating Income | -9.32 | -9.8 | -11.57 | -14.6 | -8.72 | -6.86 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.06 | 0.1 | 0.1 | 0.03 | 0.08 | 0.33 | Upgrade
|
| EBT Excluding Unusual Items | -9.27 | -9.7 | -11.47 | -14.56 | -8.64 | -6.53 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.05 | -0.17 | -0.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.04 | 0.04 | -0.04 | - | - | - | Upgrade
|
| Asset Writedown | -3.35 | -3.35 | - | -0.83 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.43 | - | - | Upgrade
|
| Pretax Income | -12.57 | -13 | -11.51 | -15.02 | -8.81 | -7.32 | Upgrade
|
| Earnings From Continuing Operations | -12.57 | -13 | -11.51 | -15.02 | -8.81 | -7.32 | Upgrade
|
| Net Income | -12.57 | -13 | -11.51 | -15.02 | -8.81 | -7.32 | Upgrade
|
| Net Income to Common | -12.57 | -13 | -11.51 | -15.02 | -8.81 | -7.32 | Upgrade
|
| Shares Outstanding (Basic) | 69 | 59 | 53 | 50 | 42 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 69 | 59 | 53 | 50 | 42 | 39 | Upgrade
|
| Shares Change (YoY) | 29.63% | 11.91% | 5.17% | 19.13% | 6.26% | 11.57% | Upgrade
|
| EPS (Basic) | -0.18 | -0.22 | -0.22 | -0.30 | -0.21 | -0.19 | Upgrade
|
| EPS (Diluted) | -0.18 | -0.22 | -0.22 | -0.30 | -0.21 | -0.19 | Upgrade
|
| Free Cash Flow | -5.01 | -5.34 | -7.36 | -7.7 | -12.27 | -13.07 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.09 | -0.14 | -0.15 | -0.29 | -0.33 | Upgrade
|
| Gross Margin | 56.21% | 54.50% | 48.52% | 48.87% | 12.58% | 2.82% | Upgrade
|
| Operating Margin | -788.17% | -728.48% | -1270.14% | -3676.32% | -971.49% | -168.57% | Upgrade
|
| Profit Margin | -1062.47% | -966.54% | -1263.01% | -3782.37% | -981.18% | -179.64% | Upgrade
|
| Free Cash Flow Margin | -423.58% | -396.80% | -807.57% | -1939.04% | -1366.37% | -320.87% | Upgrade
|
| EBITDA | -8.69 | -9.16 | -10.91 | -13.94 | -8.25 | -6.72 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -165.03% | Upgrade
|
| D&A For EBITDA | 0.63 | 0.64 | 0.66 | 0.65 | 0.48 | 0.14 | Upgrade
|
| EBIT | -9.32 | -9.8 | -11.57 | -14.6 | -8.72 | -6.86 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -168.57% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.